Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWYMJN)

Drug Name

ALN-CC5 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Haemolytic uraemic syndrome	3A21.2	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting C5 messenger RNA (C5 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cemdisiran	DM1S2FZ	Haemolytic uraemic syndrome	3A21.2	Phase 2	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT03303313) A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome. U.S. National Institutes of Health.
2	Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis. Mol Ther Methods Clin Dev. 2019 May 10;13:484-492.
3	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals.